The bar isn't set very high for approval. J&J's Remicade, the leader in the UC market with $2B in annual sales, had 39% of patients with clinical remission comparing to 15% in the placebo group.
http://www.remicadehcp.com/ulcerative-colitis...-remission
Then there are the side effects of biologics.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links